FDA to review Aveo's tivozanib

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) and partner Astellas Pharma Inc. (Tokyo:4503) said FDA accepted for review an NDA for Tivopath tivozanib to treat renal cell carcinoma (RCC). FDA did not grant ...